Trials / Completed
CompletedNCT03446625
Resveratrol as a Preventive Treatment of OHSS
Resveratrol as a Preventive Treatment of Ovarian Hyperstimulation Syndrome
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 70 (actual)
- Sponsor
- IVI Madrid · Academic / Other
- Sex
- Female
- Age
- 18 Years – 35 Years
- Healthy volunteers
- Accepted
Summary
Evaluation of resveratrol treatment oh ovarian hyperstimulation syndrome in egg donors
Detailed description
Randomized clinical trial to evaluate the role of resveratrol in preventing ovarian hyperstimulation syndrome by reducing VGEF expression and estradiol production, imporving hemoconcentration and symptomathology of this condition
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Resveratrol | Resveratrol treatment (2 g/day) will be administered for 9 days, starting from oocyte maturation day. |
| DRUG | Placebo | Placebo treatment (2 g/day) will be administered for 9 days, starting from oocyte maturation day. |
Timeline
- Start date
- 2018-03-13
- Primary completion
- 2018-10-01
- Completion
- 2019-06-01
- First posted
- 2018-02-27
- Last updated
- 2019-08-20
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT03446625. Inclusion in this directory is not an endorsement.